-
Evaluating the Efficacy and Safety of Icalcaprant in Subjects with Bipolar Depression
Official Title A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Bipolar DepressionPurpose
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population.This study will assess how safe and effective Icalcaprant is in treating adult participants with bipolar I or II disorder.
Could this study be right for you?
- Diagnosed with Bipolar Disorder I or II
- Currently in a depressive episode
- Currently receiving treatment of a mood stabilizer
Age Range
18 - 65 years -
Generalized Anxiety Disorder Study for Those Who Have Had an Inadequate Response to Antidepressants
Official Title A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant TherapiesPurpose
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.
Could this study be right for you?
- Adults 18-65
- Diagnosed with GAD
- No depressive episodes in at least 6 months
- Currently receiving treatment of either paroxetine, escitalopram, duloxetine, or venlafaxine ER
Age Range
18 - 65 years -
Living Well with Advanced Breast Cancer
Official Title Living Well with Advanced Breast CancerPurpose
The purpose of this study is to understand how patients with advanced breast cancer are using supportive care, what has helped them, what has been hard, and what kind of help they still need. Our goal is to learn from patients and caregivers about met and unmet survivorship care needs, including care that focuses on improving health and well-being of a person living with cancer.
Study participants would be asked to complete a brief survey on their demographics via phone or email. Participants will then complete a one-time interview with our study staff via zoom, phone call, or in person, depending on preference. During the interview, the study team will ask for feedback on patient and caregiver experience and needs regarding support services.
Total study participation is less than 2 hours and can be done remotely.
Could this study be right for you?
- Diagnosed with stage 4 metastatic breast cancer within the past 5 years
- A patient in the Medical Oncology Clinic at Stephanie Spielman Comprehensive Breast Center (SSCBC)
OR
- a Caregiver (could include partner, spouse, family member or close friend) of a patient meeting the above criteria
Age Range
18 - 110 years -
MARIS Study for Young Girls
Official Title Longitudinal Modeling of Interpersonal Stress Induced Rumination to Understand Depression Risk in Adolescent Girls (MARIS)Purpose
This study looks at how young girls think about and react to stress—both in their brains and in their daily lives—to see how these patterns might lead to or predict depression. It aims to understand whether certain ways of handling stress put some girls at higher risk for developing depressive symptoms.
If eligible, the child will complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI each year, for up to three years.
A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.
Could this study be right for you?
Inclusion Criteria:
- Female
- 10-14 years of age at enrollment
- Youth assent and parent consent
Exclusion Criteria:
- Psychotropic medication use in the past 4 months with the exception of ADHD medication
- Metal braces or plans for braces in the next 2 years
- Developmental disorder
- History or diagnosis of depression, substance use disorder, bipolar disorder, psychosis or seizures
- Traumatic brain injury
- Claustrophobia
Age Range
10 - 14 years -
Blocking Orexin Receptors to Help Treat Alcohol Addiction and Stress-Driven Drinking
Official Title OASIS - Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related DrinkingPurpose
This study will look at whether suvorexant can help treat alcohol use disorder, how it works, and who it works best for. Suvorexant is a medicine that blocks certain brain signals linked to wakefulness.
Your total participation time in this study will be approximately 9 weeks.
Could this study be right for you?
Inclusion Criteria:
- Age 18-65
- Participant is able to give informed consent
- Engage in heavy alcohol use defined as drinking ≥14 standard drinks per week if male and ≥7 standard drinks per week if female.
General - Exclusion Criteria
- Clinically significant medical or neurological condition (e.g., liver disease, narcolepsy, complex sleep behaviors, severe hepatic impairment, COPD, severe obstructive sleep apnea)
- Current or past DSM-5 diagnosis of mania, schizophrenia, psychosis
- Past suicide attempt within 3 years or presence of moderate suicidal ideation
- Engage in night-shift work
Age Range
18 - 65 years -
Pain Response Study in Autistic and Non-autistic Adults Ages 30-70.
Official Title Pain Sensitivity and Endogenous Pain Modulation in Autistic Adults (R21)Purpose
The purpose of this project is to study how pain may differ in adults with or without autism. Our goal is to study whether or not pain is experienced or felt differently in autistic adults compared to non-autistic adults.
Participants will be screened by phone. After meeting the initial screening criteria, the study visit will be scheduled. Participants can expect one study visit lasting 2-3 hours with time built in for breaks.
Could this study be right for you?
- Not currently on any daily pain medications
Age Range
30 - 70 years -
Study for Rural Well-Being and Social Connection
Official Title Fostering Agricultural Relationships and Meaning - Thriving on Kinship (FARM-TOK)Purpose
The purpose of this study is to understand how well and how accepted a phone-based intervention for loneliness works for people in rural or farming/agricultural areas. The goal of this intervention is to reduce loneliness and improve mental well-being.
Could this study be right for you?
Inclusion criteria
- Understand English
- Reside in an agricultural area in Ohio
- Experiencing loneliness or social isolation
Exclusion Criteria
- Limited mental competency/not able to give informed consent
- Non-English Speaking
- Diagnosis of neurological disorder or Bipolar I
- Current psychotic diagnosis
- Suicidal or homicidal intent indicating need for hospitalization or treatment (as determined by clinical interviewer)
Age Range
18 years and up -
A Study for Reducing Alcohol Use During MOUD (Phase Two)
Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)Purpose
This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.
The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.
Could this study be right for you?
Inclusion Criteria:
- engaged in MOUD treatment (for at least one month)
- alcohol consumption (within the past 12 months)
- age 18 or older
- access to a smart phone
(partial list of inclusion criteria)
Exclusion Criteria:
- diagnosis of psychosis or bipolar I
- currently pregnant (positive pregnancy test)
(partial list of exclusion criteria)
Age Range
18 years and up -
A Depression Study Examining the Effects of Lumateperone in Treatment-Resistant Depression
Official Title A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive DisorderPurpose
Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.
The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.
Could this study be right for you?
You may be able to take part if you:
• are 18–65 years of age
• have a confirmed diagnosis of Major Depressive Disorder (MDD)
• feel that your current antidepressant medication is not working well
• Has tried 2 or more antidepressant medication in the current episode of depression
Other criteria will need to be met to confirm your eligibility for this study.
Age Range
18 - 65 years -
Teen Depression Study
Official Title Developing Rumination-Focused Treatment to Reduce Risk for Depression Recurrence (RDR) in Adolescence (RuMeChange)Purpose
We are conducting a study looking at how therapy strategies can help teenagers stay healthy, reduce rumination, or overthinking and worrying, and prevent depression relapse. If eligible, the teenager would complete assessments which include clinical interviews over Zoom, surveys, cognitive testing, and an MRI.
A parent/guardian is required to enroll in the study and will complete questionnaires and a clinical interview as well.
Could this study be right for you?
Inclusion Criteria:
- 14-18 years of age at enrollment
- Youth assent and parent consent
Exclusion Criteria:
- Metal braces, tattoos with metal
- Claustrophobia
- Current pregnancy
Age Range
14 - 18 years